Pharmaceutical Formulations Inc Watch

from 8-K/A 1 page December 11, 2003 Securities and Exchange Commission 450 5th Street N.W. Washington, D.C. 20549 Gentlemen We Have Been Furnished With a Copy of the Response to Item 4 of Form 8-K for the Event That Occurred on December 10, 2003, to Be Filed by Our Former Client, Pharmaceutical Formulations, Inc. We Agree With the Statements Made in Response to That Item Insofar as They Relate to Our Firm. Very Truly Yours, /S/ Bdo Seidman, Llp Bdo Seidman, Llp

from 8-K 1 page Pharmaceutical Formulations, Inc. Announces Increased Sales and Operating Results for the Quarter and Nine Months Ended September 27, 2003 and Agreement for Development of Andas for Generic Presciption Strength Products

from 8-K 1 page Pharmaceutical Formulations, Inc. Announces Increased Sales and Improved Operating Results for the Quarter and Six Months Ended June 28, 2003

from 8-K ~20 pages Stock Purchase Agreement Among Pharmaceutical Formulations, Inc. (A Delaware Corporation), Konsyl Pharmaceuticals, Inc. (A Delaware Corporation), and Frank X Buhler, as Sole Shareholder of Konsyl Pharmarceuticals, Inc. Stock Purchase Agreement

from 8-K 1 page Pharmaceutical Formulations, Inc. Announces Award in Tesler Arbitration. Edison, Nj March 29, 2000 -- Pharmaceutical Formulations, Inc. (“Pfi” or “The Company”) (Otc: Phfr) Announced Today That an American Arbitration Association Panel in New York Has Awarded Amounts to Both the Estate of Dr. Max Tesler and to Pfi